[HTML][HTML] Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing …

S Mugusi, E Ngaimisi, M Janabi, F Mugusi… - European Journal of …, 2018 - Springer
Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with
neuropsychiatric adverse events. We investigated the time to onset, duration, clinical …

[HTML][HTML] Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without …

JK Mukonzo, A Okwera, N Nakasujja, H Luzze… - BMC infectious …, 2013 - Springer
Background HIV infection, anti-tuberculosis and efavirenz therapy are associated with
neuropsychological effects. We evaluated the influence of rifampicin cotreatment, efavirenz …

[HTML][HTML] Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz

IO Abah, M Akanbi, ME Abah, AI Finangwai, CW Dady… - Germs, 2015 - ncbi.nlm.nih.gov
Methods This retrospective cohort study utilized clinical data of HIV-1 infected adults
(aged≥ 15 years), commenced on efavirenz containing-regimen between January 2004 …

Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1–infected individuals …

A Winston, C Duncombe, PCK Li, JM Gill… - Clinical infectious …, 2010 - academic.oup.com
Background. Neurocognitive impairment remains prevalent, despite combination
antiretroviral therapy (cART). Differences between changes in cerebral function and …

[HTML][HTML] Improved central nervous system symptoms in people with HIV without objective neuropsychiatric complaints switching from efavirenz to rilpivirine containing …

JH Vera, M Bracchi, J Alagaratnam, J Lwanga, J Fox… - Brain sciences, 2019 - mdpi.com
Objective: Occult central nervous system (CNS) symptoms not recognized by people living
with HIV (PLWH) receiving efavirenz or their clinicians could occur and impact people's …

Patient reported central nervous system adverse events of efavirenz-based antiretroviral therapy in people living with HIV in Northwest Ethiopia

EA Muche, M Kiflu, MB Ayalew - HIV/AIDS-Research and Palliative …, 2020 - Taylor & Francis
Background Central nervous system (CNS) toxicities from regimens containing efavirenz are
the main reasons for non-adherence, switch and discontinuation of antiretroviral therapy …

Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape

R Gaida, I Truter, C Grobler - Southern African Journal of HIV Medicine, 2016 - ajol.info
Background: It is acknowledged that almost half of patients initiated on efavirenz will
experience at least one neuropsychiatric side effect. Objectives: The aim was to determine …

[HTML][HTML] Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a …

S Mugusi, A Habtewold, E Ngaimisi… - Frontiers in …, 2020 - frontiersin.org
Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen
during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we …

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events

DW Haas, Y Bradford, A Verma, SS Verma… - Pharmacogenetics …, 2018 - journals.lww.com
Objective We characterized associations between central nervous system (CNS) adverse
events and brain neurotransmitter transporter/receptor genomics among participants …

Depression and suicidal ideation among HIV-infected adults receiving efavirenz versus nevirapine in Uganda: A prospective cohort study

JL Chang, AC Tsai, N Musinguzi… - Annals of internal …, 2018 - acpjournals.org
Background: Evidence regarding potential adverse neuropsychiatric effects of efavirenz is
conflicting, and data from sub-Saharan Africa, where 70% of persons living with HIV (PLHIV) …